How Indonesia’s healthcare transformation will impact its IVD market March 9th, 2023 Indonesia’s in-vitro diagnostics (IVD) market will recover and grow in the 2023 to 2026 period, reversing the deep market contraction experienced in the pandemic years. The expansion of Jaminan Kesehatan Nasional (JKN) – the country’s universal healthcare system is set to increase healthcare spending and access to diagnostic tests over the coming years, driving growth in the IVD market. Clearstate Insights Centralised Diagnostics (CEDx)In-vitro diagnosticsMolecular Diagnostics (MDx)Point-of-care testing (POCT)AsiaCentralised Diagnostics (CEDx)IVD GatewayMolecular Diagnostics (MDx)Point-of-care testing (POCT)
Orthopaedic and spinal surgery devices hub With an ageing population and the rising prevalence of orthopaedic and spinal conditions, technologies and devices are being developed to treat patients more efficiently and less invasively using minimally invasive surgery (MIS) techniques and robotics. Page Orthopaedic & Spine SurgerySurgical deviceOrthopaedic & Spine SurgerySurgical Gateway
How inflation will impact Brazil’s IVD market February 21st, 2023 Brazil’s in-vitro diagnostics (IVD) market will recover in the 2023 to 2026 period and grow slightly at an average of under 1% per year, reversing the market contraction experienced in the pandemic years. The market focus will expand beyond routine tests and increasingly drive uptake of preventive tests, such as next-generation sequencing (NGS) tests for cancer and infectious diseases. Clearstate Insights Centralised Diagnostics (CEDx)In-vitro diagnosticsMolecular Diagnostics (MDx)Point-of-care testing (POCT)UncategorisedAmericas
Testing times: opportunities for IVD companies in 2023 February 13th, 2023 Growth opportunities from covid-19 have helped fuel rapid expansion for both established and emerging IVD companies. IVD companies have tapped into the increased global demand to drive growth, with some companies doubling their revenues during the pandemic years. Campaign Centralised Diagnostics (CEDx)In-vitro diagnosticsPoint-of-care testing (POCT)Tissue Diagnostics (TDx)AmericasAsiaEuropeGlobalMiddle East & Africa
APAC IVD market to shrink by 2026 as demand for covid-19 testing cools further February 9th, 2023 The Asia-Pacific (APAC) in-vitro diagnostics (IVD) market will continue to see key trends in hospital and patient care, government policies which will drive up overall diagnosis needs, and fuel fast growth for certain market segments. Find out more in our APAC IVD market update Clearstate Insights In-vitro diagnosticsAsiaIVD Gateway
Infectious Diseases Trend Monitor: India The Indian government is increasing its investment on infectious disease surveillance and research to strengthen the country’s response to emerging infectious diseases. Solutions In-vitro diagnosticsInfectious Diseases Testing MonitorAsiaInfectious Diseases Testing MonitorIVD Gateway
Drive decision-making with IVD Size & Share Plus February 6th, 2023 One of the largest IVD multinational companies plans to launch a new clinical chemistry assay in markets worldwide. To shore up their go-to-market strategy, the company needed to ensure that marketing will be tailored to achieve maximum impact in each market. Case study In-vitro diagnosticsGlobalCentralised Diagnostics (CEDx)IVD GatewaySize and Share Plus
LATAM IVD market: fastest-growing emerging market region from 2021-2026 February 2nd, 2023 The Latin America (LATAM) in-vitro diagnostics (IVD) market is expected to recover in 2024 after government measures to mitigate the worsening socioeconomic crisis amidst the Covid-19 pandemic. Find out more in our LATAM IVD market update Clearstate Insights In-vitro diagnosticsAmericasIVD Gateway
Minimally invasive and endoscopic spine surgery in Asia Pacific February 2nd, 2023 Surgical treatment of spine conditions is evolving from traditional open surgery to Minimally Invasive Surgery (MIS) and Endoscopic Spine Surgery (ESS). In the Asia-Pacific region (APAC), the demand and delivery of these less intrusive procedures is accelerating. Campaign Minimally invasive surgerySurgical deviceAsia
Infectious Diseases Trend Monitor: China China’s government is building up the country’s in vitro diagnostics (IVD) testing capacity to strengthen the country’s response to infectious diseases. The government is expected to invest more than Rmb 15.6bn in 2023 on infectious diseases prevention and control, targeting diseases including HIV, tuberculosis and other severe infectious diseases such as covid-19. Solutions In-vitro diagnosticsInfectious Diseases Testing MonitorAsiaInfectious Diseases Testing MonitorIVD Gateway
Andrew Salomone Viteritti Andrew leads The Economist Intelligence Unit’s analysis on international commerce and regulations. He manages The EIU’s Country Commerce team, which produces comprehensive evaluations on the commercial regulatory environment across 56 major economies worldwide. He also serves as a senior member of The EIU’s Global Forecasting and broader Editorial operations. Andrew’s research focuses on key regulatory issues involving international trade, investment, competition, labour, migration and development, among other policy areas. He has served as an advisor and consultant on a number of policy projects at The EIU and other leading institutions. He frequently presents to various audiences, including policymakers and universities. Person AmericasEuropeGlobal
Asia-Pacific infectious disease diagnostics market trends January 27th, 2023 In Asia-Pacific (APAC), many countries continue to build up in vitro diagnostics (IVD) testing capacity to strengthen the country’s response to infectious diseases. Clearstate expects infectious disease testing to grow. Clearstate Insights In-vitro diagnosticsInfectious Diseases Testing MonitorUncategorisedAsiaInfectious Diseases Testing MonitorIVD Gateway